Approximately one-third of patients with lung cancer will develop airway obstruction and many cancers lead to airway obstruction through metastases. The treatment of malignant airway obstruction is often a multimodality approach and is usually performed for palliation of symptoms in advanced lung cancer. Removal of airway obstruction is associated with improvement in symptoms, quality of life, and lung function. Patient selection should exclude patients with short life expectancy, limited symptoms, and an inability to visualize beyond the obstruction. This review outlines both the immediate and delayed bronchoscopic effect options for the removal of airway obstruction and preservation of airway patency with endobronchial stenting.
INTRODUCTION
Although bronchoscopy has progressed since 1897-when a German physician, Gustav Killian, removed a pork bone from the right main bronchus that had been aspirated by a Blackforest worker a bronchoscope he had created-the indications are similar (to diagnose and treat airway disease), the devices are similar (an illuminated scope, long and narrow enough to reach the airway), and the limitations are the same (the size of the scope as opposed to the reducing diameter of the airway) [1] . This was the beginning of modern bronchoscopy. Today bronchoscopy has developed into two distinct areas, diagnostic and therapeutic. Two types of bronchoscope are available: the rigid bronchoscope, developed by Chevalier Jackson in the 1920s; and the flexible bronchoscope, developed by Shigeto Ikeda in the 1960s, and this article will highlight the similarities and differences in these devices [2, 3] .
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In the USA, lung cancer causes approximately as many deaths as the next four leading causes of cancer death combined [4] . Approximately 220,000 patients are diagnosed with lung cancer each year in the USA [4] . Onethird of lung cancers cause malignant airway obstructions (MAO) with associated symptoms [5] . Multiple metastatic malignancies can also cause MAO including thyroid, kidney, colon, esophageal, breast, and melanoma [see Video 1 in the electronic supplementary material (ESM)]. Symptoms of MAO include cough, dyspnea, hemoptysis, and symptoms related to post-obstructive pneumonia in patients with or without a prior cancer diagnosis. The target of treatment is to re-establish and/or maintain airway patency, achieve stability, and allow other cancer-targeted therapy with the intention of improving symptoms, quality of life, functional status, and lung function [5] [6] [7] [8] . This review article is aimed at the respiratory physicians, especially those with a subspecialty interest in bronchoscopy. The contents reflect much of the current international guidelines [5] [6] [7] [8] . The main focus of this article is for a comprehensive review of therapeutic bronchoscopy in the management of MAO. This review article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
MULTIMODALITY APPROACH
Patients with MAO should have a multidisciplinary team discussion in centers with expertise in the all possible interventions [6] [7] [8] . Interventions include bronchoscopic therapy, external beam radiation, and chemotherapy [6] [7] [8] . This article does not deal with treatment of MAO by external beam radiation which is covered in guidelines elsewhere [9] . This article will give an outline each of the immediate effect and delayed effect bronchoscopic modalities ( Fig. 1 ; Table 1 ) for the treatment of MAO with a section dedicated to endobronchial stents. Bronchoscopic intervention is often multimodality with most centers offering a subset of modalities rather than all procedures available (Figs. 2, 3 ). Given the fact that bronchoscopic treatment of MAO is usually a palliative procedure in patients with advanced lung cancer, it is as important that trainees in bronchoscopy learn when and when not to intervene as it is to learn how to intervene.
The target of intervention should include improvement in symptoms and quality of life,
and not just to remove a visualized obstruction in the airway. In general, if the bronchoscopist cannot visualize normal airway beyond the obstruction on bronchoscopy or imaging, if life expectancy is short regardless of intervention, or if the patient has advanced cancer with little symptomatology due to immobility, bronchoscopic intervention should be avoided.
It is also important to emphasize that no metaanalysis and limited prospective studies with objective measures are available on the role of multimodality therapeutic bronchoscopy. Two small studies of 37 and 20 patients identified improvements in dyspnea and quality of life, with documented improvements in lung function, after bronchoscopic treatment for MAO [10, 11] . Complication rates ranged from 3% to 8%. Prospective data on long-term complication rates, such as infection and restenosis from multimodality approaches to MAO, is also lacking. One recent retrospective study highlighted an increased risk of respiratory infections in patients undergoing airway treatment of MAO with as opposed to without stent insertion [12] .
Due to the fact that the majority of patients with MAO secondary to lung cancer have locally advanced or advanced disease, therapeutic bronchoscopic interventions are in the majority palliative and are rarely curative. Early assessment by a palliative care team in these patients improves outcomes [13] . 
RIGID OR FLEXIBLE BRONCHOSCOPY
Although comparisons will be made between both rigid and flexible bronchoscopy, both have their advantages in different scenarios but should be seen as complimentary procedures to each other [16, 17] . Rigid bronchoscopy is defined as the trans-oral or trans-tracheotomy passage of rigid instruments for diagnosis or In summary, electrocautery, in experienced hands, is a safe, cheap, and effective therapy for early stage and advanced cancer with MAO [6] [7] [8] .
Argon Plasma Coagulation
In interventional bronchoscopy, argon plasma coagulation (APC) has two main roles: to resect MAO and to control endobronchial bleeding APC superior to electrocautery and laser photoresection in achieving hemostasis [35] . Crosta et al. [36] found that 92% of 47 patients treated with APC achieved airway recanalization and localized hemostasis. APC has been used in the setting of metastatic disease, for example, malignant melanoma, to recanalize airways [37] .
In summary, APC is a cheap, safe, and effective modality for treating both MAO and hemoptysis [6] [7] [8] .
Laser
The use of laser in bronchoscopy started almost three decades ago when Strong and Jako in 1972 used a CO 2 laser to treat various laryngeal disorders and the following year went on to use this modality to treat endobronchial lesions [38] . Bronchoscopic laser resection is a useful modality in the treatment of MAO, particularly exophytic proximal airway lesions. Airway obstruction, secondarily to bronchogenic carcinoma, is the most frequent indication for laser resection [39, 40] . It may also be employed for a Thermal laser is an effective modality in the treatment of malignant endobronchial lesions. For the past four decades, the outcome data regarding bronchoscopic laser resection has been very encouraging. It appears to be an immediate and relatively safe way to manage malignant endobronchial lesions [45, 46] . A large study by Cavaliere et al. [47] in 1988 demonstrated the effectiveness of thermal laser in managing malignant endobronchial tumors.
A rigid bronchoscope was used in 1,280 (92%) of the treatments, with patients almost always under general anesthesia; 116 (8%) treatments were performed with the flexible fiber-optic bronchoscope alone, with the use of local anesthesia. In almost all cases of localized carcinoid tumors, the treatment was curative [47] . Another case series by Cavaliere et al. [48] demonstrated that airway patency and symptoms were improved in over 90% of cases, and mortality was less than 1%. Nd:YAG laser intervention is safe and effective for palliation of endobronchial malignancies. In most cases, it only needs to be performed once [48] . Compared with Nd:YAG laser therapy alone, multimodal treatment, which includes stent insertion, brachytherapy, chemotherapy, and radiotherapy together with Nd:YAG laser therapy, has demonstrated prolonged survival, suggesting the benefits of a combined approach [49] . One study of 99 patients with MAO demonstrated an improvement in dyspnea, lung function, and performance status in patients with partially occluded airways, but it was felt that physicians underestimated the severity of patients symptoms compared to the patients themselves which must be borne in mind when interpreting symptomatic relief statistics [50] .
A cheaper endobronchial laser is now available [neodymium:yttrium-aluminum perovskite (Nd:YAP)]. Thus far, there are limited data on the usefulness of this laser in MAO; however, applications and complications are similar to the Nd:YAG laser. One study of 133 patients with various malignant and benign (7 patients) indications concluded that the Nd:YAP laser was a safe and effective tool for bronchoscopy [51] . No direct comparisons are available.
In summary, laser through bronchoscopy is an effective approach for treatment MAO.
ND:YAG laser is more expensive, may not be available in many centers, and requires training in safety to prevent injury to patients and staff [6] [7] [8] .
Microdebridement
The microdebrider has been used for nearly 30 years by otorhinolaryngologists for upper airway endoluminal lesions including laryngeal carcinomas [52] . A microdebrider operates by using a powered rotating blade and a simultaneously operating suction device to facilitate the removal of debris. A recent case report demonstrated excellent results with an elongated rotating tip microdebrider to about 45 cm (Fig. 2 ) [53] . The advantages of microdebridement are that it is accurate and allows high flow oxygen which is contraindicated in other thermal ablation procedures, such as APC, thermal laser, and electrocautery. However, APC or electrocautery may be required to achieve hemostasis.
Microdebridement has been shown in a retrospective analysis of 23 patients to be successful treatment of tracheal granulation tissue, idiopathic subglottic stenosis, and MAO [54] . The complications of thermal modalities, such as airway injury, tracheoesophageal fistulas, and airway fires, can be avoided using microdebridement. The main complications of microdebridement are those pertaining to bronchoscopy, hemorrhage, perforation, and pneumothorax [55] .
INTERVENTIONAL BRONCHOSCOPY: DELAYED EFFECT

Bronchoscopic Cryotherapy
First described in 1812 to help achieve hemostasis and analgesia in surgical amputee during the Russian campaign, cryotherapy is a cheap and effective treatment for many medical conditions [56, 57] . Bronchoscopic cryotherapy is an interventional bronchoscopic procedure where, either through rigid or flexible bronchoscopy, malignant or benign tissue is ablated by repeatedly freezing, thawing, and refreezing (Fig. 4) . The first reported use of bronchial cryotherapy was by Sanderson et al. [58] in 1975. The mechanisms of cryotherapyinduced cytotoxicity are well established. The tissue destruction caused by cryotherapy causes a coagulative necrosis in a tumor. The initial freezing of target tissue causes it to stick to the probe. Following this there is both extracellular and intracellular ice formation which causes disruption of cellular enzymes and cell membrane integrity. When the cell thaws water returns to the cell quickly (at freezing the extracellular region becomes hypertonic causing water to move out of the cell). This rapid return of intercellular water causes cell lysis [59, 60] . The area of destruction through cryotherapy has a diameter of 1 cm when a 3-mm diameter probe is used. When in lateral contact with a bronchial wall, cytotoxicity can be considered complete to a depth of 3 mm [59, 60] . Non-hemorrhagic necrosis of the tissue [7, 62] . Increased cell death is proportional to the amount of time at which the low temperatures are maintained, but this increases complication rates [59, 60] . The recommended temperature is -40°C as this will destroy the tumor cell line that might be resistant to destruction at -20°C [60] . A repeat bronchoscopy needs to be performed to remove necrotic debris about 3-6 days later. There is another newer method, cryoextraction, which employs an endotracheal airway to remove tissue at the time of cyroablation. Cryoextraction causes immediate results and so could be used to treat acute tracheal or bronchial obstruction [63, 64] . There are two types of probes available: a liquid nitrogen probe, which is very powerful but awkward to use, and a nitrous oxide (N 2 O)-driven cryoprobe. Flexible cryoprobes of 2-3 mm in diameter are available and can be used through a flexible fiber-optic bronchoscope [65] .
Usually, between 3 and 30 treatments, each lasting 20 s, are required. The procedure is relatively painless. About 1-2 weeks after cryotherapy, necrotic tissue is sloughed off and expectorated or removed if a repeat bronchoscopy is performed.
The effects are excellent with a wellvascularized tumor such as carcinoid and carcinoma. Vergnon et al. [60] reports a cure rate of 100% in endobronchial carcinoid treated with both laser-assisted mechanical resection followed by cryotherapy. Cryotherapy has also been indicated for in situ carcinoma where cure is the intention [66] . Cryotherapy may also be indicated for and has been used in the treatment of low grade malignant tumors such as lymphoma, adenoid cystic carcinoma, and in carcinoma in situ [66] [67] [68] . Cryotherapy has been used in a case series in patients with endobronchial carcinoid tumors [63] . It has also been utilized against metastatic deposits in the main airway. It is very effect in controlling hemoptysis secondarily to its remarkable effect on tumor vascularization [11, 69] . Seon-Heui et al. [70] [72] .
In summary, cryotherapy may be considered for MAO in patients without critical airway narrowing. Its main advantage, in a similar to fashion to microdebridement, is that there is no limitation in oxygen delivery during the procedure [6] [7] [8] .
Brachytherapy
Endobronchial brachytherapy (EB) is an invasive two step technique. The first step in brachytherapy is to identify the target lesion and the second step is to remotely, under fluoroscopy and computer guidance, place the radioactive source (usually 1 mm 3 in size) beside the target lesion, and also involves minute changes in its position in a staged process to allow irradiation on the target lesion. Yankauer [73] [5] . ''Low dose rate'' (LDR) has been distinguished from ''high dose rate'' (HDR)
brachytherapy [76] . LDR brachytherapy is less than 2 Gy/h and a maximum of 1,500-5,000 cGy over 3 days. It requires inpatient treatment for up to 3 days and is costly and cumbersome with radiation protection measures. HDR is about 12 Gy/h with the dose varying from 100 to 300 cGy (calculated at 10 mm from the source axis).
HDR allows placement through the tip of a hallow catheter to the tumor site for a much shorter period of time which is less costly than LDR and enhances the patient experience [76, 77] . Upon decision of type of brachytherapy and identification of lesion, the irradiated length is marked by external tags controlled by fluoroscopy. A guide wire is placed through the bronchoscope and the irradiation applicator is placed over this by the Seldinger technique [76] . A dummy seed in first placed and its position is confirmed with a set of orthogonal chest radiographs. Once correct positioning has been confirmed the applicator is connected to the Iridium-192 source and then advanced down to the target lesion. When in place the radiation source is moved in 5 mm intervals in periods of time decided on by oncology algorithms at the lesion site [78, 79] . High doses of radiation can be safely administered with little collateral damage to healthy surrounding tissues [80] . Follow-up bronchoscopy is advised 3-6 weeks after treatment. EB was initially dedicated to a palliative setting; with symptoms improving in 60-88% of procedures and an endoscopic response rate of 30-100% [81] . The benefits of EB over external beam radiation are the precision targeting of a lesion with larger dosage of radiation and the limiting of damage to surrounding tissues. A report has also described the use of a modified airway stent to approximate brachytherapy catheters to a carinal lesion [82] .
The major use of EB is for the palliation of symptoms related to MAO. It is not indicated to and 29%, respectively, while the 2-and 5-year cancer-specific survival rates were 81% and 56%, respectively [87] . HDR brachytherapy was associated with a complete endoscopic response rate of 94% at 120 days [87] . A 2008 Cochrane review of palliative EB for NSCLC analyzed 13 randomized controlled trials but could not combine them into a meta-analysis because of heterogeneity in the doses of radiotherapy delivered, patient characteristics, and outcomes measured [85] . The authors concluded that EBRT alone is still more effective for palliation of symptoms than EB alone. Their findings did not provide conclusive evidence that EB plus EBRT improved symptom relief over external beam radiation alone, nor did it improve complication rates or extend survival. In summary, the authors were not able to provide conclusive evidence to recommend EB as an add-on to first-line EBRT, chemotherapy or Nd:YAG laser palliative treatment [85] . For patients previously treated by EBRT who are still symptomatic, EB may be considered an option [85, 88] . Indeed there is some evidence to support the addition of EB to EBRT for local control [88, 89] . Two randomized trials compared EB to EBRT with or without EB.
Improvements in the combined modality were identified in the arm of one trial and were short lived. The second trial identified that both EB and EBRT improved symptoms, with EBRT performing better but with more acute morbidity. The rate of fatal hemoptysis was high at 7-15% [90, 91] .
Complications of EB include those of regular bronchoscopy. Initially, patients may complain of increased bronchial secretions and severe cough. Patients with poor performance status are at higher risks of respiratory failure [85] .
Some patients experience pleuritic chest pain.
Airway perforation, causing pneumothorax or mediastinitis, can occur. As with external beam radiation treatment radiation bronchitis and bronchial stenosis is a recognized complication.
The most important complications are fistula formation and massive hemoptysis with a prevalence of 10% [76, 84, 85] . There exists evidence that squamous cell carcinoma of the main stem bronchi is a risk factor for fatal hemoptysis [92] .
Contraindications to EB include patients with high-grade occlusive endotracheal or proximal bronchial lesions as the treatment causes edema which could lead to lifethreatening airway obstruction. EB is also proscribed in patients with imminent danger of fistula formation between the airway and other structure. Patients with a high level of airway obstruction should be treated with either Nd:YAG laser and/or stent placement before brachytherapy. EB is relatively contraindicated in patients who have a life expectancy of less than 3 months [76, 84, 85] .
In summary, brachytherapy is effective in the palliation of both endobronchial and peribronchial malignancy with a delayed effect. There is a significant risk of hemoptysis [6] [7] [8] .
Photodynamic Therapy
Modern oncologic treatment by drug-light interactions dates back to 1903 in treating skin cancers [93] . Photodynamic therapy (PDT) has a long and successful clinical track record for both malignant and benign conditions (acne vulgaris or hemorrhagic hereditary telangiectasia) [94, 95] . Bronchoscopic PDT was first used with success in Japan in 1982 in a patient with lung cancer who refused surgery [96] . That patient died 4 years later from an unrelated cause [96] . In lung cancer, PDT has been used cure early stage endobronchial lung tumors as well as the ability to palliate central endobronchial obstruction [60, [103] [104] [105] [106] [107] . PDT has also been used with success to treat superficial occult shallow lesions, local recurrence, distal endobronchial obstruction, endobronchial metastases of non-pulmonary malignancies, and hemoptysis from an endobronchial arteriovenous malformation [60, 106] . One study of 133 patients with obstructive airway lesions led to an improvement in dyspnea and hemoptysis in 74% and 99% of cases, respectively [51] . Photodynamic therapy may be considered as an alternative treatment for patients under consideration for surgical treatment for stage I carcinoma in whom the risk of surgery is high [108] . Diaz-Jiménez et al. [109] compares the efficacies of PDT and Nd:YAG laser therapy for the palliation of symptoms caused by malignant endobronchial obstruction. Their results for both modalities appear to be similar when directly compared in patients with inoperable NSCLC [109] . The advantages of PDT over Nd:YAG laser therapy is it does not produce endobronchial smoke and can be performed in an oxygen-rich environment (i.e., hypoxic patients requiring supplementary oxygen). PDT has been successfully combined with other endobronchial therapies, including brachytherapy and laser therapy [60, [109] [110] [111] .
The complications of PDT are those of routine bronchoscopy and those specific to PDF. Certainly, sunburn up to 6 weeks post HPD administration is a concern and patients need to be fully informed to avoid sunlight and to wear appropriate clothing. Sunscreen has little if any benefit. Other complications are hemoptysis, bronchopleural fistula formation, fibrotic stenosis, and bronchial necrosis. PDT is contraindicated in patients with an allergy to the photosensitizer, patients who have porphyria, and in those patients with lifethreatening obstruction or malignancy involving any major blood vessels or the esophagus.
In summary, PDT is effective in debulking and palliation with delayed effect and no limitation of oxygenation in MAO [6] [7] [8] .
Airway Stents
Airway stents, also known as tracheobronchial prostheses, are tube-shaped devices that are inserted into an airway to maintain airway patency. Airway prostheses or stents made of metal, silicone, or other materials can be used to relieve airway obstruction caused by malignant tumors ( Fig. 2 [120, 121] .
It is advisable that a stenotic lesion should be dilated or debrided as far as safely possible to get the best possible benefit from stent insertion. Bronchoscopic debridement of tumor is first performed to remove as much endoluminal obstruction as possible, and thus stent placement should be considered to maintain long-term airway patency. Even though bronchoscopy is frequently used to deploy airway stents, tracheobronchial stent insertion can be accomplished using fluoroscopic guidance alone [121] . The diameter of the stent should be about 1-2 mm greater than the estimated normal diameter of the airway.
Stent sizing varies according to the airway and length of stenosis. Follow-up bronchoscopy is indicated if symptoms recur [122, 123] .
Regarding symptom relief in MAO, seven studies are available with a variety of airway stents [82, [123] [124] [125] [126] [127] [128] [129] . In a series of 40 patients with MAO, the severe dyspnea index improved in 34 of 39 patients within 24 h of stent insertion [130] . In patients with acute respiratory failure due to malignant MAO requiring mechanical ventilation, stenting is associated with weaning from ventilatory support. In one series this was achieved in 14 of 26 patients with MAO, 21 of whom had malignancy [131] . A 2005 study of 172 stents placed in 140 patients with MAO was encouraging [132] . The mean follow-up period was around 150 days. There were 23 complications, including tumor ingrowth (n = 9), excessive granulation tissue (n = 7), stent migration (n = 5), and restenosis (n = 2 Fistula formation after stent placement is a long-term complication of stent placement [133] [134] [135] [136] . Razi et al. [124] found that timely stenting of the airway, before the morbid complications of malignant central airway obstruction have set in, resulted in improved survival. A recent single center retrospective review of MAO compared complication rates in 72 patients with and without stent insertion [12] . The majority of stents placed were either self-expandable metal or hybrid stents. There were more infections in those in whom stents were placed. The authors concluded that a strategy of initially holding off on stent placement should be considered in those patients with removal of airway obstruction who may respond to external beam radiation and/or chemotherapy [12] .
In summary, after removal of endobronchial obstruction through debulking, stents can be considered to maintain airway patency [6] [7] [8] .
Self-expandable metal stents should not be placed in patients where removal is considered in the future. 
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